Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons by Chattopadhyay, A. et al.
INFECTION AND IMMUNITY, Apr. 2004, p. 1956–1963 Vol. 72, No. 4
0019-9567/04/$08.000 DOI: 10.1128/IAI.72.4.1956–1963.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis
in Human Immunodeficiency Virus Type 1-Infected Persons
Amit Chattopadhyay,1 Laurie R. Gray,1 Lauren L. Patton,1 Daniel J. Caplan,1 Gary D. Slade,2
Hsaio-Chuan Tien,3 and Diane C. Shugars1,4*
Schools of Dentistry,1 Public Health,3 and Medicine,4 University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina, and School of Dentistry, University of Adelaide, Adelaide, Australia2
Received 5 September 2003/Returned for modification 14 October 2003/Accepted 5 January 2004
Oropharyngeal candidiasis, typically caused by Candida albicans, is the most common oral disease associated
with human immunodeficiency virus type 1 (HIV-1) infection. Secretory leukocyte protease inhibitor (SLPI), a
12-kDa antiprotease, suppresses the growth of C. albicans in vitro. To determine whether the mucosal protein
plays a role in protecting oral tissues against fungal infection, we conducted a cross-sectional study investi-
gating the oral and systemic health and salivary SLPI levels in 91 dentate HIV-1-infected adults receiving
medical care in the southeastern United States. Participants with a self-reported history of clinical oropha-
ryngeal candidiasis during the previous 2 years constituted the test group (n  52), while the comparison group
(n  39) had no oropharyngeal candidiasis during that period. Data collected from medical records, oral
examination, and SLPI enzyme-linked immunosorbent assay quantitation of whole saliva were analyzed by t
test, analysis of variance, linear regression, and unconditional logistic regression. The test group had a
significantly higher mean salivary SLPI level than the comparison group (1.9 g/ml versus 1.1 g/ml, P <
0.05). Linear regression modeling identified CD4 cell count and history of oropharyngeal candidiasis as key
predictors of salivary SLPI and revealed a significant interaction (P < 0.05) between immunosuppression
(CD4 cell count below 200 cells/l) and positive history of oropharyngeal candidiasis in predicting salivary
SLPI level. By logistic regression modeling, a salivary SLPI level exceeding 2.1 g/ml, low CD4 count,
antiretroviral monotherapy, and smoking were key predictors of oropharyngeal candidiasis. These data sup-
port a key role for SLPI in the oral mucosal defense against C. albicans. The antimicrobial mucosal protein may
serve as an indicator of previous oropharyngeal candidiasis infection among immunosuppressed persons.
Oropharyngeal candidiasis, typically caused by Candida al-
bicans, is the most frequent opportunistic oral disease in per-
sons infected with human immunodeficiency virus (HIV) and
other immunosuppressive conditions (12, 33). Although the
microorganism is a harmless commensal in the oral cavity of
healthy individuals, C. albicans can rapidly proliferate, invade
tissues, and cause symptomatic mucosal lesions in immuno-
compromised persons (12). Oropharyngeal candidiasis is a sen-
tinel indicator of immunodeficiency and HIV disease progres-
sion (20, 34). The asymptomatic presence of C. albicans in the
oral cavity increases the likelihood of developing clinical dis-
ease, especially following immune suppression (4, 11, 13). In a
cross-sectional study conducted by Campisi and colleagues (4),
62% of HIV-1-positive persons harbored Candida species in
their oral cavity, compared to 29% of HIV-1-negative persons.
In a recent longitudinal study, Ohmit and coworkers (32)
found the acquisition and prevalence rates of oral Candida
colonization and candidiasis to be eightfold higher among
HIV-1-seropositive women compared to at-risk uninfected
women.
Multiple host defense mechanisms control the proliferation
and invasion of C. albicans in the oral cavity (28). Systemic
cell-mediated immunity is considered the key host defense
mechanism against this microorganism, as evidenced by the
high incidence of oropharyngeal candidiasis in patients with
reduced CD4 T lymphocyte counts (CD4 counts) (12). A role
for local cell-mediated immunity is suggested by a shift from a
Th1- to Th2-type cytokine profile in the saliva of HIV-infected
persons with oral candidal lesions (24). Humoral immunity is
not considered a critical protective defense, as persons with
and without oropharyngeal candidiasis exhibit similar Candi-
da-specific antibody responses in saliva (44). Much less is
known about the importance of soluble endogenous antimicro-
bial peptides and proteins such as salivary histatins, lactoferrin,
and defensins in the natural resistance of oral tissues against C.
albicans (25).
Antifungal activity has been recently described for the anti-
microbial mucosal protein secretory leukocyte protease inhib-
itor (SLPI; also known as antileukoprotease and mucus pro-
tease inhibitor) (40). The 12-kDa single-chained polypeptide is
secreted by epithelial cells lining the mucosal surfaces of the
oral, nasal, respiratory, and reproductive tracts (16). Tomee et
al. (42) reported that recombinant SLPI inhibited the in vitro
growth of C. albicans and Aspergillus fumigatus. Recombinant
SLPI also killed the yeast form of C. albicans in a dose-depen-
dent manner at concentrations ranging from 2 to 15 M, with
over 80% fungicidal activity at 15 M. The antifungal activity
of recombinant SLPI was localized to its amino-terminal do-
main, distinct from the antiprotease and antibacterial func-
tional sites residing in its carboxyl-terminal domain (10). Be-
cause these experiments were conducted under low-salt
conditions (10 mM sodium phosphate buffer), it is not clear
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whether SLPI has antifungal activity under physiological con-
ditions.
Although SLPI was initially characterized from parotid
gland secretions (31), little is known of the role that the cat-
ionic protein plays in oral mucosal disease. Most studies of
SLPI function have been conducted in the respiratory tract
(17), reproductive system (8), and skin (1). As the major serine
protease inhibitor in upper airway cells (17) and neutrophils
(37), SLPI protects mucosal membranes from attack by neu-
trophil elastase during inflammation (35). The mucosal protein
also blocks the in vitro replication of HIV-1 (19, 29, 38-41, 43),
non-HIV-1 viruses (influenza A and Sendai viruses) (2), and
bacteria (Escherichia coli and Staphylococcus aureus) (18), and
promotes cutaneous wound healing in mice (1, 45). Thus, sal-
ivary SLPI may play a role in the innate oral mucosal defense
against pathogenic microorganisms such as C. albicans.
To date, no published studies have investigated either the
predictors of salivary SLPI or the relationship between salivary
SLPI and Candida infection in vivo. The current investigation
examined the level of salivary SLPI in relation to CD4 cell
count and history of oropharyngeal candidiasis among HIV-1-
infected individuals while controlling for antifungal medica-
tions, smoking, and other factors. The study also evaluated
whether salivary SLPI may serve as an indicator of previous
oral candidal infection in this immunosuppressed population.
MATERIALS AND METHODS
Study population. The cross-sectional analysis included 91 dentate adult per-
sons and was nested within a cohort study of 631 HIV-positive persons followed
for 2 years at the University of North Carolina Hospitals, Chapel Hill, N.C. The
participants in the current study included all subjects of the larger cohort study
who had at least four teeth in all quadrants of the mouth and provided saliva
samples. For the current study, the test group consisted of 52 participants who
had a history of oropharyngeal candidiasis at any time during the 2 years pre-
ceding and including the study visit, while the comparison group was comprised
of 39 participants who had no history of oropharyngeal candidiasis during that
period. Written informed consent was obtained from each participant prior to
enrollment, according to the University of North Carolina (UNC) Institutional
Review Board.
Questionnaire, clinical examination, and medical record review. Before the
clinical examination, a trained social researcher administered a detailed ques-
tionnaire to collect data describing sociodemographics and smoking history. A
single calibrated dental examiner trained in oral medicine and blinded to the
participant’s questionnaire responses performed a comprehensive oral examina-
tion for HIV-associated oral diseases, following standard clinical criteria (9).
White and red areas caused by trauma or friction were ignored. A diagnosis of
oropharyngeal candidiasis was based solely on clinical appearance and included
the pseudomembraneous, erythematous, and angular cheilitis forms; no staining,
cytology, or culture was performed. After the clinical examination, the medical
record for each participant was reviewed to obtain data describing CD4 count,
viral load in blood (typically within 2 months of the study visit), and current
antiretroviral and antifungal medication use.
Saliva collection and salivary SLPI quantitation. Participants refrained from
eating and toothbrushing for at least 30 min before saliva collection. Whole
(mixed) unstimulated human saliva was collected by expectoration into chilled
sterile containers as we have described (40) and stored at 70°C within 2 h of
collection. Samples were later thawed, mixed briefly, and analyzed for SLPI
content with a commercial human SLPI enzyme-linked immunosorbent assay
(ELISA) (R&D Systems, Minneapolis, Minn.).
Data management. This study analyzed variables from the interview question-
naire, medical record review, examination findings, and salivary SLPI quantita-
tion. Data were double entered, checked for consistency, crosschecked, and
synchronized with the medical records and interview questionnaire.
Due to the small number of participants with clinically detected oropharyngeal
candidiasis at the study visit, the intermittent nature of oropharyngeal candidiasis
(11, 12), and the high prevalence of Candida carriage reported among HIV-1-
positive individuals (4, 32), we used a history of oropharyngeal candidiasis as a
surrogate indicator of oropharyngeal candidiasis. In support of this decision, a
recent study by the Centers for Disease Control and Prevention found a self-
reported history of oropharyngeal candidiasis to be a good predictor of clinical
oropharyngeal candidiasis, as evaluated by repeat-measure analysis (6). To di-
rectly test this reasoning in our study population, we created a composite three-
level candidiasis variable: history of oropharyngeal candidiasis only, current
oropharyngeal candidiasis plus history of oropharyngeal candidiasis, and neither
current oropharyngeal candidiasis nor history of oropharyngeal candidiasis. No
participant had current oropharyngeal candidiasis without a history of oropha-
ryngeal candidiasis, so this level was not needed.
Based on the previously reported mean salivary SLPI level of 1.2 g/ml in an
HIV-1-positive cohort (40), we calculated that this study had 80% power for a
minimum detectable difference of 0.455 g/ml in salivary SLPI levels between
participants with and without a positive history of oropharyngeal candidiasis,
with a two-tailed test at an alpha of 0.05. For some analyses, salivary SLPI levels
were dichotomized, with a cutoff value of 2.1 g/ml. This value was the minimal
concentration that reduced Candida growth in vitro (42) and was equal to the
mean level plus three times the standard deviation for mean salivary SLPI
concentration in a cohort of HIV-1-positive persons (40).
Statistical analyses. Statistical analyses were performed with SAS (version 8.2;
SAS, Cary, N.C.). Differences in mean salivary SLPI levels between test and
comparison groups were evaluated based on CD4 count groups and viral load
groups with the t test, one-way analysis of variance, and chi-square tests.
The goals of the multivariable analyses were to determine whether salivary
SLPI levels were different between those with and without a positive history of
oropharyngeal candidiasis after adjusting for important variables and to develop
an explanatory model for salivary SLPI level by finding the best-fitting and most
parsimonious yet biologically reasonable model to describe the relationship
between the outcome and explanatory variables. Linear regression models to
predict salivary SLPI were generated with continuous salivary SLPI as the out-
come and candidal status, smoking status, and categorized CD4 levels and viral
load as the explanatory variables. Interaction terms were tested with history of
oropharyngeal candidiasis status as the main explanatory variable. The main-
effects model and the interaction terms were assessed with a chunkwise test.
Variables that were statistically not significant were removed to arrive at a
parsimonious final model. If any statistical interaction became evident, analysis
for the involved variables was limited to simple effects within their categories.
Predicted salivary SLPI values were examined against observed values. Another
model similar to the final model was evaluated by replacing the categorical CD4
count variable with CD4 count as a continuous variable. Predicted salivary SLPI
levels were plotted and, in case of interactions, mean salivary SLPI levels in the
CD4 cell groups were tested between levels of the stratifying variables. Uncon-
ditional logistic regression models with Proc Logistic were analyzed with dichot-
omized salivary SLPI as the outcome variable to evaluate predictors of high
salivary SLPI levels.
For all multivariable analyses, the hierarchically well-formulated model prin-
ciple (21) was used; for any given variable in the model, all lower-order compo-
nents of the variables must also be contained in the model. To arrive at a final
model, we tested hierarchical sets of models with the likelihood ratio test. Where
present, interactions were assessed through the interaction contrast ratio (ICR).
With Rothman and Greenland’s notations (36), ICR  RR11  RR01  RR10
 RR00; where ICR is the relative excess risk for interaction, whereas RR01 and
R10 are the odds ratios for exposure to any one of the exposures, RR11 is the
odds ratio for doubly exposed, and R00 is the unitary value for the referent
(doubly unexposed group). Regression diagnostics were performed, and the
utility of the models was evaluated by outputting predicted scores and residuals.
A secondary goal of the analyses was to evaluate the usefulness of a dichot-
omous high/low salivary SLPI variable as an explanatory variable for history of
oropharyngeal candidiasis as an outcome and to control for confounding. Un-
conditional logistic regression was performed as described above to model the
probability of positive history of oropharyngeal candidiasis.
RESULTS
Study population characteristics. Table 1 summarizes the
characteristics of the study population. Most participants were
black, male, and between 30 and 39 years of age and were not
taking an antifungal medication. Approximately half were cur-
rent tobacco smokers, while 24.4% were former smokers and
21.1% had never smoked. The majority (83.3%) had CD4
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counts below 500 cells/ml, the threshold below which oral man-
ifestations typically appear (33). Approximately half of the
population currently used combination antiretroviral therapy
and had plasma viral loads below 2.0  104 copies/ml.
A majority (52 of 91, or 57.1%) of the participants had had
at least one episode of oropharyngeal candidiasis during the
previous 2 years. Current oropharyngeal candidiasis, in its
pseudomembraneous, erythematous, or angular cheilitis form,
was detected at the examination in 13 (14.3%) participants.
Oral hairy leukoplakia (13 participants) and linear gingival
erythema (4 participants) were the only other HIV-associated
oral lesions detected in the study population.
Salivary SLPI levels and oral candidal disease. The mean
( standard error) salivary SLPI concentration for the study
population was 1.45  0.19 g/ml (median, 0.79 g/ml), which
is comparable to the mean salivary SLPI level that we previ-
ously described in a different HIV-1-infected cohort (40). Sal-
ivary SLPI levels for study participants according to candidal
status are shown in Fig. 1. The mean salivary SLPI level was
significantly higher among participants with a history of oro-
pharyngeal candidiasis (1.99  0.80 g/ml) compared to par-
ticipants with no history of oropharyngeal candidiasis (1.11 
0.16 g/ml, t test, P  0.04, Fig. 1A). At the time of the study
visit, the mean salivary SLPI level was comparable between
participants with and without current oropharyngeal candidi-
asis (1.71  0.56 g/ml versus 1.41  0.20 g/ml, P  0.05, Fig.
1B).
Using analysis of variance, we found no significant difference
between salivary SLPI levels based on the composite candidi-
asis variable (model P  0.71, Fig. 1C). Therefore, we were
confident in using a history of oropharyngeal candidiasis as our
test definition for additional analyses. With this definition,
participants with a previous oropharyngeal candidiasis episode
had a slightly lower mean CD4 count (211  61 cells/l) and
somewhat higher mean viral load in plasma (1.2  105  5.0 
105 copies/ml) compared to participants without an oropha-
ryngeal candidiasis episode (395  31 cells/l and 5.7  104 
4.1  104 copies/ml, respectively); however, the differences
failed to reach statistical significance. The collective data sug-
gest that salivary SLPI levels are elevated in immunosup-
pressed individuals who have experienced a previous episode
of oropharyngeal candidiasis.
Impact of CD4 cell count and history of oropharyngeal can-
didiasis on salivary SLPI levels. We assessed the relationship
of systemic immunosuppression (CD4 counts) and salivary
FIG. 1. Salivary SLPI (salSLPI) levels and oral candidiasis (OC) in
an HIV-1-infected population. The SLPI content of saliva from each
participant was measured by ELISA and compared with their history
of oropharyngeal candidiasis (H/o OC, panel A), current oropharyn-
geal candidiasis (panel B), and both history of and current oropharyn-
geal candidiasis (panel C). P values were determined by t test or
analysis of variance (*, significantly different).
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SLPI level with oropharyngeal candidiasis experience. In biva-
riable analyses, participants with low CD4 counts (below 200
cells/l) were five times as likely as those with higher CD4
counts (200 cells/l or greater) to have a positive history of
oropharyngeal candidiasis (crude odds ratio  5.1; 95% con-
fidence interval  1.9, 13.9). Those with higher salivary SLPI
levels were 2.5 times as likely as those with low salivary SLPI
levels to have a positive history of oropharyngeal candidiasis
[odds ratio  2.5 (0.6, 7.3)]. When stratified by salivary SLPI
levels, the odds ratios for CD4 and history of oropharyngeal
candidiasis varied between low salivary SLPI (odds ratio  9.5)
and high salivary SLPI (odds ratio  1.0) levels, the ratio of the
two stratum-specific odds ratios being 9.5. The Breslow-Day
chi-square statistic (3.9/1 df, P  0.04, general association P 
0.0006) suggested heterogeneity of odds ratios between the
salivary SLPI strata, indicating modification of the effect of
CD4 on candidal status by salivary SLPI levels.
To determine whether mean salivary SLPI levels differed
between participants based on oropharyngeal candidiasis ex-
perience after adjusting for key variables, linear regression
models were developed with salivary SLPI as a continuous-
outcome variable and history of oropharyngeal candidiasis,
smoking status, and categorized CD4 level and viral load as
explanatory variables. Table 2 shows the full and final linear
regression models for predicting salivary SLPI as a continuous
outcome. Viral load in plasma, antifungal medications, and
smoking were not significant factors in the full model and were
removed to develop the final model. Explanatory variables that
significantly contributed to both models were low CD4 count
(below 200 l) and a positive history of oropharyngeal candi-
diasis. The final model with categorical CD4 levels was: sali-
vary SLPI  0.946  0.780 g/ml (if CD4 count is 200
cells/l, 0 otherwise)  1.298 g/ml (if history of oropharyn-
geal candidiasis is positive, 0 otherwise)  1.743 g/ml (if CD4
count is 200 and if history of oropharyngeal candidiasis is
positive, 0 otherwise).
A significant interaction between low CD4 count and oro-
pharyngeal candidiasis experience was detected in the linear
regression model predicting the salivary SLPI value as a con-
tinuous variable (P  0.004, Table 2). The graph for the inter-
action is shown in Fig. 2. According to this linear regression
model, salivary SLPI levels among participants with a positive
history of oropharyngeal candidiasis are predicted to increase
with increasing CD4 counts. The opposite trend of lower sal-
ivary SLPI level with increasing CD4 count, however, is pre-
dicted among those without a history of oropharyngeal candi-
diasis. These results support the odds ratio heterogeneity
between salivary SLPI strata identified in the bivariate analyses
described above and suggest that salivary SLPI levels are mod-
ified by immune status and candidal experience.
Logistic regression models were also used to predict salivary
SLPI as a dichotomous outcome (high versus low, with 2.1
g/ml as the cutoff). As shown in Table 3, viral load in plasma,
use of antifungal medication, and smoking were not significant
factors and were removed to develop the final model. The
interaction term P value just reached the alpha value of 0.05.
We retained the term in the final model because interaction
tests are known to have low power (36), and the P value came
to the statistical threshold of 0.05.
Further examination of the interaction between candidal
experience and CD4 count (Table 3) revealed that participants
with a positive history of oropharyngeal candidiasis and higher
FIG. 2. Salivary SLPI (salSLPI) levels from the linear regression
model were plotted for participants with and without a positive oro-
pharyngeal candidiasis history, with CD4 count as a continuous vari-
able, to demonstrate the interaction between CD4 cell count and
history of oropharyngeal candidiasis (H/o OC) as related to salivary
SLPI level.
TABLE 2. Linear regression source table, parameter estimates, and model equations for outcomes of continuous salivary SLPI and
continuous CD4 cell counta
Variable
Full model with continuous
salivary SLPI
Final model with continuous
salivary SLPI
Final model with continuous
CD4 count
Est SE P Est SE P Est SE P
Intercept 1.534 0.542 0.006 0.946 0.311 0.003 1.520 0.487 0.002
CD4 cell count (continuous), cells/l 0.001 0.001
CD4 count 200 cell/l* 0.446 0.887 0.780 0.686
CD4 count 200–500 cells/l* 0.358 0.545 0.514
Viral load 50,000 copies/ml* 0.175 0.506 0.730
Viral load 20,000–50,000 copies/ml* 0.317 0.592 0.594
Current smoker (yes  1) 0.523 0.410 0.206
History of candidiasis (yes  1) 1.527 0.515 1.298 0.476 0.401 0.590
CD4 count 200 and history of candidiasis 2.000 0.935 0.036 1.743 0.841 0.004
CD4 cell count (continuous) and history of candidiasis 0.004 0.002 0.012
a Est, estimate; *, indicator variable.
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CD4 counts were six times as likely to have a high salivary SLPI
level as those with no history of oropharyngeal candidiasis and
high CD4 count (odds ratio  5.94), supporting the model
shown in Fig. 2. With a positive history of oropharyngeal can-
didiasis and low CD4 cell count as the two exposure groups,
the interaction of candidal status with CD4 cell count was
significant: ICR  1.64  2.62  5.94  1.00  5.92 (i.e.,
subadditive). Therefore, the risks for individual exposures do
not add up mathematically to the risk for the doubly exposed.
In biological terms, this finding suggests that other mechanisms
might be involved in completely explaining relationships
among CD4 cell count, history of oropharyngeal candidiasis,
and salivary SLPI.
Effects of salivary SLPI on history of oropharyngeal candi-
diasis. Although our primary outcome variable of interest was
salivary SLPI, we also wanted to determine the usefulness of a
dichotomous high/low salivary SLPI categorization as an ex-
planatory variable for positive history of oropharyngeal candi-
diasis as an outcome and control for confounding. Thus, un-
conditional logistic regression models were developed,
modeling the probability of having a positive history of oro-
pharyngeal candidiasis. As shown in Table 4, high salivary
SLPI level, low CD4 count, anti-HIV monotherapy, and smok-
ing were significant contributors to an oropharyngeal candidi-
asis episode. Here, too, we found the interaction explained
earlier involving salivary SLPI, oropharyngeal candidiasis ex-
perience, and CD4 count, in that the relationship between
CD4 count and history of oropharyngeal candidiasis was sig-
nificantly modified by the salivary SLPI level. The ICR of
21.84 suggests subadditivity and supports the earlier finding
that other factors likely influence the relationship among sal-
ivary SLPI, CD4 count, and history of oropharyngeal candidi-
asis.
DISCUSSION
In this first investigation of potential antifungal activity by
SLPI in vivo, we examined the associations between salivary
SLPI and viral, immunologic, and oral health parameters
within an HIV-1-infected population. High Candida carriage
has been demonstrated among HIV-1-positive persons (4, 11,
12), and oropharyngeal candidiasis is found in 95% of AIDS
patients (27). Although our study did not determine carriage
rates, we used a history of oropharyngeal candidiasis as a
surrogate measure for high candidal carriage. Given the low
prevalence of clinically apparent oropharyngeal candidiasis le-
sions among study participants, the strategy allowed reason-
able power to detect meaningful associations between salivary
SLPI and history of oropharyngeal candidiasis. In our study,
participants with a positive history of oropharyngeal candidia-
sis had significantly higher levels of salivary SLPI than partic-
ipants without an oropharyngeal candidiasis episode (P 
0.05). Positive history of oropharyngeal candidiasis and high
CD4 count were predictive of salivary SLPI production regard-
less of whether salivary SLPI was evaluated as a continuous or
dichotomous outcome. In additional analyses, salivary SLPI
was a key explanatory variable for history of oropharyngeal
candidiasis, suggesting that the mucosal protein may serve as
an indicator of candidal status in immunocompromised indi-
viduals. Together with the reported in vitro antifungal activity
TABLE 3. Logistic regression model for predicting dichotomous
salivary SLPI outcome with cutoff at 2.1 g/mla
Parameter
Full model Final model
Est SE P Est SE P
Intercept 1.82 0.83 0.02 1.87 0.54 0.0005
CD4 count (cells/ml)
200 1.27 1.09 0.96 0.99
200 Refb Ref
History of candidiasis
Yes 2.02 0.75 1.78 0.69
No Ref Ref
CD4 count and history of
candidiasis
200/ml, yes 2.61 1.30 0.04 2.25 1.19 0.05
200/ml, no Ref Ref
Antifungal medicine
Yes 0.79 0.13, 4.96 0.80
No Ref
Viral load (copies/ml)
20,000 1.94 0.57, 6.53 0.28
20,000 Ref
Smoking
Former 0.56 0.12, 2.63 0.46
Current 0.41 0.11, 1.57 0.19
Never Ref
a Values are estimates (Est) and standard error for the first four parameters
and odds ratios and 95% confidence intervals for the last three parameters. In
the evaluation of the interaction between oral candidiasis experience and CD4
cell count, ICR  RR11  RR10  RR01  1; therefore, ICR  1.64  2.62 
5.94  1  5.92. The odds ratios for the final model (adjusted estimates) were:
positive history and CD4 count of 200/l, 1.64; positive history and CD4 count
of 200/l, 5.94; negative history and CD4 count of 200/l, 2.62; and negative
history and CD4 count of 200/l, 1.00 (Ref).
b Ref, reference.
TABLE 4. Logistic regression model for predicting the probability of positive history of oral candidiasisa
Parameter Estimate SE Odds ratio 95% confidenceinterval P
Intercept 2.31 0.91 0.01
CD4 (200 cells/l  1; 200 cells/l  0) 2.34 0.70
Anti-HIV medication (monotherapy  1; none  0) 2.01 0.86 0.13 0.03, 0.72 0.01
Anti-HIV medication (combination therapy  1; none  0) 0.93 0.65 2.53 0.71, 9.03 0.15
Smoking (ever  1; never  0) 1.53 0.76 4.62 1.05, 20.37 0.04
Salivary SLPI (2.1 g/ml  0; 2.1 g/ml  1) 3.00 0.96
Salivary SLPI and CD4 cell count 3.31 1.47 0.02
a In the evaluation of the interaction between salivary SLPI level and CD4 cell count group, ICR  RR11  RR10  RR01  1; therefore, ICR  7.61  10.37 
20.08  1  21.84. The odds ratios for the final model (adjusted estimates) were salivary SLPI  2.1 g/ml and CD4 count 200/l, 7.61; salivary SLPI  2.1 g/ml
and CD4 count 200/l, 20.08; salivary SLPI  2.1 g/ml and CD4 count 200/l, 10.37; and salivary SLPI  2.1 g/ml and CD4 count 200/l, 1.00 (reference).
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of SLPI (42), the data support a role for salivary SLPI in the
local oral defense against C. albicans.
It is intuitively appealing to expect higher salivary SLPI
levels among participants without an oropharyngeal candidia-
sis history based on SLPI’s candidicidal activity in vitro (42).
Due to our study design, we could not identify the temporal
association between salivary SLPI elevation and development
of oropharyngeal candidiasis. In our study, it is likely that
salivary SLPI production was upregulated in response to oro-
pharyngeal candidiasis infection in an attempt to inactivate the
pathogenic microorganisms and resolve the clinical disease.
Despite elevated salivary SLPI levels, which may be limited
physiologically to an individualized threshold, the oral de-
fenses were overwhelmed by the fungal infection, and clinical
disease was recognized by participants who reported a positive
history of oropharyngeal candidiasis. Furthermore, partici-
pants in the test group had already been exposed to Candida
organisms at the time of saliva collection. Therefore, it is likely
that their salivary SLPI values represent levels close to their
individual thresholds. In such a situation, an increase in sali-
vary SLPI is expected to be associated with greater odds of
being a participant with previous or current oropharyngeal
candidiasis.
The overall candidal burden and species of candidal micro-
organisms colonizing oral tissues may have altered the oral
salivary SLPI levels. Because tests to confirm the presence and
identity of microbes were not performed on the saliva speci-
mens, we could not evaluate this hypothesis. This potentially
important issue should be addressed in future studies.
Systemic and local cell-mediated immunity responses likely
influence local salivary SLPI production and oral disease, un-
derscoring the interplay between the innate and cell-mediated
immune responses against C. albicans. Subclinical candidal
infection may promote the maintenance of high salivary SLPI
levels due to immune dysfunction in the oral cavity that alters
salivary SLPI regulation such that a high level is maintained
even after the infection is resolved. In support of this idea,
immunohistochemical analyses have localized CD8 T cells to
the interface of the lamina propria and submucosa in oropha-
ryngeal candidiasis lesions in HIV-infected individuals, a loca-
tion that is distant from the outer layers of the epithelium
where active Candida infection occurs (30). In an immune
dysfunctional state, especially when CD4 cell numbers are
sharply reduced, CD8 T cells may be important for host
defense against oropharyngeal candidiasis (30). Also, the sys-
temic immunosuppression characteristic of HIV-1 infection
modifies the normal immune responses in the oral cavity, as
evidenced by altered antibody and cytokine responses in saliva
(3, 7, 23) and reduced numbers of Langerhans dendritic cells
(26) and CD4 T cells (30) in the oral mucosa of HIV-1-
infected persons.
The relationship between salivary SLPI and history of oro-
pharyngeal candidiasis persisted after adjustment for other
potential confounding factors. The associations between oro-
pharyngeal candidiasis, immunosuppression, and viremia are
well documented (14, 15, 22, 34). In our study, participants
with high salivary SLPI levels were more likely to have had an
oropharyngeal candidiasis episode than those with low salivary
SLPI levels after adjusting for CD4 count, antiretroviral med-
ication, and smoking (Tables 2 and 3). These findings suggest
that salivary SLPI is a previously unidentified independent
indicator of oropharyngeal candidiasis history.
Linear regression modeling showed a significant interaction
between immunosuppression and positive history of oropha-
ryngeal candidiasis in predicting high salivary SLPI content.
Among participants with a positive history of oropharyngeal
candidiasis, the odds of having a high salivary SLPI level when
mildly to moderately immunosuppressed was 3.6-fold higher
than in those with severe immunosuppression (odds ratios,
5.94 versus 1.64, Table 3). In contrast, among participants
without an oropharyngeal candidiasis experience, the odds ra-
tio for having a high salivary SLPI level was twofold higher
among those with CD4 counts below 200 cells/l compared to
those with counts above this threshold (odds ratios, 2.62 versus
1.00, Table 3). These results suggest that an intact immune
system is needed to generate a strong salivary SLPI response
among individuals with oral candidal disease but not in dis-
ease-free individuals. With history of oropharyngeal candidia-
sis as the outcome variable (Table 4), logistic regression mod-
eling confirmed the interaction of salivary SLPI, candidal
history, and CD4 count.
In an attempt to explain candidal experience in terms of
CD4 count, salivary SLPI levels, and other important variables,
we considered cigarette smoking as a potential factor in the
models predicting salivary SLPI and history of oropharyngeal
candidiasis. In a recent study of pulmonary oxidative stress,
mice exposed to cigarette smoke exhibited a 50% reduction in
SLPI antiprotease activity compared to unexposed mice (5).
Although we found lower salivary SLPI levels among current
smokers, the difference was not statistically significant, and
smoking did not significantly contribute to the model for pre-
diction of salivary SLPI as either a continuous or dichotomous
outcome variable (Tables 2 and 3). However, smoking was
associated with a fourfold increase in the odds of having a
positive history of oropharyngeal candidiasis [odds ratio, 4.62
(1.05, 20.37), P  0.04] even after adjusting for covariates,
including salivary SLPI (Table 4). From these observations, we
speculate that while cigarette smoke suppresses salivary SLPI
levels (as among smokers who report no oropharyngeal candi-
diasis episode), exposure to Candida species may lead to an
upregulation of salivary SLPI (as among smokers who report a
positive history of oropharyngeal candidiasis) that may over-
come the suppressive effects of smoking.
Our study suggests that upregulation of the anti-inflamma-
tory protein contributes to the mucosal defense of oral tissues
against Candida infection. It is possible that other inflamma-
tory conditions or microbial infections coexisting with oropha-
ryngeal candidiasis, such as periodontal or HIV-associated oral
pathogens, could also trigger an increase in salivary SLPI.
Therefore, future studies of SLPI function in the oral cavity
should take into account possible confounding influences by
competing disease groups and local inflammatory conditions
that may influence salivary SLPI production.
Several salivary peptides and proteins, including the cationic
peptides, histatins, defensins and the antimicrobial protein lac-
toferrin, inhibit C. albicans growth in vitro (25). Based on our
current findings, SLPI joins the growing list of endogenous
antifungal factors that may serve as potential therapeutic
agents for preventing and/or treating candidal infections. More
study is needed to determine the relative antifungal activities
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of these factors in oral secretions. Longitudinal investigation of
salivary SLPI gene expression and protein production in pa-
tients with and without clinical oropharyngeal candidiasis will
give further insight into the antimicrobial role of this protein in
the oral cavity.
In conclusion, this study demonstrated that a history of oro-
pharyngeal candidiasis is a strong independent predictor of
salivary SLPI level in an HIV-1-positive population and that
the salivary SLPI-oropharyngeal candidiasis relationship is
modified by overall immune status. Elevated salivary SLPI
production may be a defensive oral response to Candida attack
in HIV-1-infected persons. Upregulation of the antimicrobial
mucosal protein may serve as a biomarker for oropharyngeal
candidiasis, particularly in immunosuppressed persons, and
warrants further investigation.
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Whitman. 2002. Secretory leukocyte protease inhibitor: inhibition of human
immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly
cloned protein. Bioorg. Chem. 30:249–263.
39. Shugars, D. C., D. L. Sauls, and J. B. Weinberg. 1997. Secretory leukocyte
protease inhibitor blocks infectivity of primary monocytes and mononuclear
1962 CHATTOPADHYAY ET AL. INFECT. IMMUN.
cells with both monocytotropic and lymphocytotropic strains of human im-
munodeficiency virus type I. Oral Dis. 3(Suppl. 1):S70–S72.
40. Shugars, D. C., A. L. Alexander, K. Fu, and S. A. Freel. 1999. Endogenous
salivary inhibitors of human immunodeficiency virus. Arch. Oral Biol. 44:
445–453.
41. Skott, P., E. Lucht, M. Ehnlund, and E. Björling. 2002. Inhibitory function
of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1
specific and varies with virus tropism. Oral Dis. 8:160–167.
42. Tomee, J. F. C., P. S. Heimstra, R. Heinzel-Wieland, and H. F. Kauffman.
1997. Antileukoprotease: an endogenous protein in the innate mucosal de-
fense against fungi. J. Infect. Dis. 176:740–747.
43. Wahl, S. M., T. B. McNeely, E. N. Janoff, D. Shugars, P. Worley, C. Tucker,
and J. M. Orenstein. 1997. Secretory leukocyte protease inhibitor (SLPI) in
mucosal fluids inhibits HIV-I. Oral Dis. 3(Suppl. 1):S64–S69.
44. Wozniak, K. L., J. E. Leigh, S. Hager, R. K. Swoboda, and P. L. Fidel, Jr. 2002.
A comprehensive study of Candida-specific antibodies in saliva of HIV-infected
persons with oropharyngeal candidiasis. J. Infect. Dis. 185:1269–1276.
45. Zhu, J., C. Nathan, W. Jin, G. S. Ashcroft, S. M. Wahl, L. Lacomis, H.
Erdjument-Bromage, P. Tempst, C. D. Wright, and A. Ding. 2002. Conver-
sion of proepithelin to epithelins: roles of SLPI and elastase in host defense
and wound repair. Cell 111:867–878.
Editor: T. R. Kozel
VOL. 72, 2004 SALIVARY SLPI AND ORAL CANDIDIASIS 1963
